TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25910800

Group type: EXPERIMENTAL
Intervention: Intermittent ECG recordings over 2 weeks
Number of subjects: 7173

Group type: EXPERIMENTAL
Intervention: Initiation of OAC treatment
Number of subjects: 7173

Group type: COMPARATOR
Intervention: Known AF without OAC treatment
Number of subjects: 7173

Group type: COMPARATOR
Intervention: Total AF prevalence
Number of subjects: 7173

Group type: COMPARATOR
Intervention: Screening program
Number of subjects: 7173
Study: 24220161

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 2173

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 2173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2173

Group type: COMPARATOR
Intervention: Combined vitamin A+zinc
Number of subjects: 2173
Study: 21668975

Group type: EXPERIMENTAL
Intervention: CHO-P group (whey protein plus carbohydrate drink)
Number of subjects: 17

Group type: COMPARATOR
Intervention: CO group (water)
Number of subjects: 17
Study: 19507410

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 60

Group type: COMPARATOR
Intervention: Povidone-iodine solution
Number of subjects: 60
Study: 17107615

Group type: EXPERIMENTAL
Intervention: Antithrombin therapy (6,000 IU bolus followed by 250 IU/hour for four days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Antithrombin therapy
Number of subjects: 33
Study: 15033097

Group type: EXPERIMENTAL
Intervention: Group intervention (3 sessions lasting approximately 1.5 hours each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimum intervention (brief personal counselling for 3 to 5 minutes)
Number of subjects: 0
Study: 11251525

Group type: EXPERIMENTAL
Intervention: Knee-elbow position (KE)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Left-lateral position (LL)
Number of subjects: 117
Study: 10395119

Group type: EXPERIMENTAL
Intervention: Fungolon (test)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diflucan (reference)
Number of subjects: 18
Study: 8895284

Group type: EXPERIMENTAL
Intervention: 5% lidocaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 50
Study: 1854075

Group type: EXPERIMENTAL
Intervention: Inhalation rewarming
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Peripheral rewarming
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhalation rewarming and peripheral rewarming evaluated separately or in combination
Number of subjects: 8
Study: 6889154

Group type: EXPERIMENTAL
Intervention: sulfisoxazole at 500 mg twice a day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: pneumococcal immunization
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: both pneumococcal vaccine and 500 mg sulfisoxazole twice daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: no routine medication
Number of subjects: 72

Group type: COMPARATOR
Intervention: antihistamines whenever nasally congested
Number of subjects: 72
Study: 30885256

Group type: EXPERIMENTAL
Intervention: CBT + physical exercise
Number of subjects: 70

Group type: COMPARATOR
Intervention: CBT + telephone calls
Number of subjects: 70
Study: 29395554

Group type: EXPERIMENTAL
Intervention: Experimental group (n=22)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 43
Study: 26740092

Group type: COMPARATOR
Intervention: Teacher professional development intervention delivered partially via the Internet, including two workshops and implementation tasks over 6 months, followed by a booster period of 3 months with additional workshops and mentoring.
Number of subjects: 0
Study: 24493368

Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt
Number of subjects: 48
Study: 22127270

Group type: EXPERIMENTAL
Intervention: 300 mg EGCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 19409341

Group type: EXPERIMENTAL
Intervention: Headgear (HG) treatment started immediately with no other appliances used during the first 2 years
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group with only minor interceptive procedures during the first 2 years
Number of subjects: 68
Study: 17765616

Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 60, mean daily dose of 46 +/- 9 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metoprolol (n = 60, mean daily dose of 93 +/- 11 mg)
Number of subjects: 120
Study: 15124719

Group type: EXPERIMENTAL
Intervention: Tongue‐muscle training (20 minutes twice a day for 8 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 67
Study: 12641016

Group type: EXPERIMENTAL
Intervention: Covered stent grafts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional stents
Number of subjects: 0
Study: 9849815

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) at a fixed daily dose of 8 microg/kg birthweight
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 7853127

Group type: EXPERIMENTAL
Intervention: GTR procedure using the resorbable synthetic material (experimental)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mucoperiosteal flap debridement procedure without barrier placement (control)
Number of subjects: 40
Study: 2596736

Group type: EXPERIMENTAL
Intervention: IV aminophylline (6 mg/kg over fifteen minutes)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31501133

Group type: EXPERIMENTAL
Intervention: HABIT‐ILE intervention (6.5 hours per day for 10 days, total 65 hours)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care (waitlisted for 26 weeks)
Number of subjects: 126
Study: 28328148

Group type: EXPERIMENTAL
Intervention: XR-NTX (extended-release naltrexone)
Number of subjects: 168
Study: 26350388

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg/90 mg twice daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: High-dose clopidogrel (150 mg/day)
Number of subjects: 48
Study: 23493898

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NIRS measures of cerebral oxygenation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (neonate controls)
Number of subjects: 18
Study: 22027321

Group type: EXPERIMENTAL
Intervention: NovoPen 4
Number of subjects: 116

Group type: COMPARATOR
Intervention: NovoPen 3
Number of subjects: 116
Study: 19692680

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg per day)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (carboplatin dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute plus paclitaxel 200 mg per square meter of body-surface area)
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Gefitinib in patients with EGFR mutation
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel in patients without EGFR mutation
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 1217
Study: 16467543

Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (160 mg twice a day)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 15566590

Group type: EXPERIMENTAL
Intervention: Intervention strategy with additional cytokine measurements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine sepsis work up
Number of subjects: 0
Study: 11130223

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by clinical pharmacists
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 208
Study: 9249645

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8391686

Group type: EXPERIMENTAL
Intervention: Rapid succession (5 sec apart)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30-second intervals and shaking MDI between two rapid activations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30-second intervals and shaking between each activation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 60-second intervals and shaking between each activation
Number of subjects: 8
Study: 2952160

Group type: EXPERIMENTAL
Intervention: 30 degrees head down position for 30 min post-operation
Number of subjects: 131

Group type: COMPARATOR
Intervention: Flat position post-operation (control group)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Falope rings for sterilization
Number of subjects: 131

Group type: COMPARATOR
Intervention: Hulka clip sterilization or diagnostic laparoscopy (control for Falope rings)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 131
Study: 30572544

Group type: EXPERIMENTAL
Intervention: Soft non‐manipulative osteopathic techniques (1 session every 10 days for 30 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 30
Study: 27078181

Group type: EXPERIMENTAL
Intervention: Meta-awareness with identification
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Meta-awareness with disidentification
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control
Number of subjects: 138
Study: 25704652

Group type: EXPERIMENTAL
Intervention: Glimepiride (GL) 3mg/d + ketotifen 1mg twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Glimepiride (GL) 3mg/d + ketotifen 1mg once daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Glimepiride (GL) 3mg/d alone
Number of subjects: 48
Study: 23143410

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (20 cc)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo (20 cc 5% dextrose solution)
Number of subjects: 223
Study: 20966212

Group type: EXPERIMENTAL
Intervention: Perceptual-motor intervention (2 times per week for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Home program (1 time per week for 8 weeks)
Number of subjects: 50
Study: 19043129

Group type: EXPERIMENTAL
Intervention: Uncemented trabecular metal tibial components
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cemented tibial components
Number of subjects: 41
Study: 15924982

Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone
Number of subjects: 534

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study: 12486284

Group type: EXPERIMENTAL
Intervention: Hypocretin‐1 (hcrt‐1) measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypocretin‐2 (hcrt‐2) measurement
Number of subjects: 0
Study: 9892449

Group type: EXPERIMENTAL
Intervention: Nortriptyline and IPT
Number of subjects: 187

Group type: COMPARATOR
Intervention: Nortriptyline and medication clinic visits (placebo)
Number of subjects: 187

Group type: COMPARATOR
Intervention: IPT and placebo
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo and medication clinic visits
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Combined treatment with nortriptyline and IPT
Number of subjects: 187
Study: 8670319

Group type: EXPERIMENTAL
Intervention: Progressive resistance muscle strength training for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Swimming-only control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation with tumor necrosis factor alpha (TNF alpha)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation with growth hormone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation with plasma glucagon levels
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation with growth hormone and glucagon
Number of subjects: 24
Study: 2070058

Group type: EXPERIMENTAL
Intervention: Natural interferon-alpha (nIFN-alpha) therapy at doses of 3 million IU, three times a week
Number of subjects: 59

Group type: COMPARATOR
Intervention: Recombinant interferon-alpha-2a (rIFN-alpha-2a) therapy
Number of subjects: 59
Study: 6225762

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 41
Study: 29105879

Group type: EXPERIMENTAL
Intervention: Unguided self-help version (n=146)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Guided intervention with adherence-focused guidance by eCoaches (n=144)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Control group on a waiting list with full access to usual care (n=144)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Combined intervention groups (unguided and guided)
Number of subjects: 578
Study: 28133385

Group type: EXPERIMENTAL
Intervention: Rehabilitation programme with a treadmill with visual feedback function (n = 23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 46
Study: 24836312

Group type: EXPERIMENTAL
Intervention: Pirfenidone (2403 mg per day)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 22614874

Group type: EXPERIMENTAL
Intervention: Clopidogrel + Aspirin (75 mg/day + 100 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 57
Study: 19387817

Group type: EXPERIMENTAL
Intervention: Sexually explicit video (n = 20)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Neutral video (n = 20)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Humor video (n = 19)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Anxiety provoking video (n = 20)
Number of subjects: 79
Study: 18269638

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp) thrice-daily regimen
Number of subjects: 604

Group type: COMPARATOR
Intervention: Biphasic human insulin (BHI) 30 group
Number of subjects: 604
Study: 15933797

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 28
Study: 12689395

Group type: EXPERIMENTAL
Intervention: 4.7F ureteral stent
Number of subjects: 46

Group type: COMPARATOR
Intervention: 6F ureteral stent
Number of subjects: 46
Study: 10773786

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparotomic cholecystectomy
Number of subjects: 100
Study: 8823850

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg)
Number of subjects: 72
Study: 1448739

Group type: EXPERIMENTAL
Intervention: Single dose (750 milligrams) prophylactic cefamandole delivered directly into the operative wound with local anesthesia
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 324
Study: 2410571

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation with moderate pressure over a large area
Number of subjects: 24
Study: 30289509

Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CA)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 300
Study: 30142111

Group type: EXPERIMENTAL
Intervention: C-Port vein grafts
Number of subjects: 117

Group type: COMPARATOR
Intervention: Hand-sewn grafts
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: C-Port device
Number of subjects: 117
Study: 26713321

Group type: EXPERIMENTAL
Intervention: Periorbital cooling
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cooling (control)
Number of subjects: 50
Study: 25172603

Group type: EXPERIMENTAL
Intervention: HDR-BRT (30Gy/12 fractions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 3D-CRT (50Gy/25 fractions)
Number of subjects: 64
Study: 22138585

Group type: EXPERIMENTAL
Intervention: 2 polyethylene glycol (PEG) drops
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEG drops
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CMC drops
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEG and CMC drops
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (CMC, PVA, glycerine drops)
Number of subjects: 23
Study: 19739124

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 8389

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 8389
Study: 17399621

Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy (group A)
Number of subjects: 100
Study: 16342903

Group type: EXPERIMENTAL
Intervention: Gd-DTPA-BMA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gd-DOTA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gd-DTPA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (non-contrast MRI)
Number of subjects: 10
Study: 10704165

Group type: EXPERIMENTAL
Intervention: ACD CPR plus ITV
Number of subjects: 21

Group type: COMPARATOR
Intervention: ACD CPR alone
Number of subjects: 21
Study: 9129857

Group type: EXPERIMENTAL
Intervention: Community-wide smoking cessation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison community (control)
Number of subjects: 0
Study: 8419612

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg/m2 nightly)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Growth Hormone therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 10
Study: 3541274

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 311

Group type: COMPARATOR
Intervention: Vaccine
Number of subjects: 311
Study: 29614245

Group type: EXPERIMENTAL
Intervention: RSV-positive patients
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Influenza-positive patients
Number of subjects: 1200
Study: 26527204

Group type: EXPERIMENTAL
Intervention: Oral appliances (OAs)
Number of subjects: 9
Study: 23867247

Group type: EXPERIMENTAL
Intervention: Xifeng Dingchan Pill (XFDCP) with Madopar for early-stage PD (n = 80)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Xifeng Dingchan Pill (XFDCP) combined with Madopar and Piribedil for middle-stage PD (n = 80)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Madopar for early-stage PD (n = 80)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Madopar and Piribedil for middle-stage PD (n = 80)
Number of subjects: 320
Study: 21912473

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 1888
Study: 18318267

Group type: EXPERIMENTAL
Intervention: Influenza vaccination co-payments
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Influenza vaccination subsidies
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Total price of influenza vaccination
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vaccine uptake rates
Number of subjects: 300
Study: 17144453

Group type: EXPERIMENTAL
Intervention: Central tenotomy of levator aponeurosis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lengthening of Mullers' muscle combined with levator muscle
Number of subjects: 22
Study: 12743150

Group type: EXPERIMENTAL
Intervention: letrozole
Number of subjects: 562

Group type: COMPARATOR
Intervention: tamoxifen
Number of subjects: 562
Study: 10764480

Group type: EXPERIMENTAL
Intervention: 0.5 mg nitroglycerin
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 0.25 mg nitroglycerin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physiologic sodium chloride solution (placebo)
Number of subjects: 62
Study: 9184388

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant hirudin (HBW 023)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Intravenous sodium heparin
Number of subjects: 155
Study: 1530173

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine (112.5 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.25% bupivacaine (112.5 mg)
Number of subjects: 44
Study: 3652468

Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (1000 IU)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (3000 IU)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 39
Study: 28104042

Group type: EXPERIMENTAL
Intervention: Audit of medical records
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Audit of discharge summaries
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Evidence of discharge summary distribution
Number of subjects: 200
Study: 27333004

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using resorbable minimembrane and particulate xenograft (DBBM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inductive periodontal regeneration (IPR) using enamel matrix derivatives and DBBM
Number of subjects: 20

Group type: COMPARATOR
Intervention: GTR
Number of subjects: 20

Group type: COMPARATOR
Intervention: IPR
Number of subjects: 20
Study: 24095004

Group type: EXPERIMENTAL
Intervention: Semirigid (small) titanium plates
Number of subjects: 127

Group type: COMPARATOR
Intervention: Rigid (large) titanium plates
Number of subjects: 127
Study: 23248825

Group type: EXPERIMENTAL
Intervention: Audiovisual patient safety vignettes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional methods of instruction (lecture and written case studies)
Number of subjects: 24
Study: 20552291

Group type: EXPERIMENTAL
Intervention: Childhood ALL survivors
Number of subjects: 21

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 21
Study: 18544618

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 16 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (matched control subjects)
Number of subjects: 24
Study: 20921315

Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg loading dose followed by 50 mg every 12 hours)
Number of subjects: 0
Study: 15730366

Group type: EXPERIMENTAL
Intervention: Tension‐free Vaginal Tape (TVT)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Intravaginal Sling (IVS)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Suprapubic Arc Sling (SPARC)
Number of subjects: 195
Study: 12049012

Group type: COMPARATOR
Intervention: Conventional absorbable subcutaneous Polyglactin 910 (VICRYL, ETHICON) and non absorbable cutaneous Monofilament Nylon (ETHILON, ETHICON) stitches
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Running subcutaneous and intradermic irradiated Polyglactin 910/370 (VICRYL‐Rapide, ETHICON) sutures
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VICRYL‐Rapide
Number of subjects: 50
Study: 9623020

Group type: EXPERIMENTAL
Intervention: Cefoperazone/sulbactam (25 mg/kg/day) + co-trimoxazole (8 mg/kg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ceftazidime (100 mg/kg/day) + co-trimoxazole (8 mg/kg/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 84